149 related articles for article (PubMed ID: 31521738)
1. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
Nakashima M; Suzuki N; Shiraishi E; Iwashita H
Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
[TBL] [Abstract][Full Text] [Related]
5. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.
Redrobe JP; Jørgensen M; Christoffersen CT; Montezinho LP; Bastlund JF; Carnerup M; Bundgaard C; Lerdrup L; Plath N
Psychopharmacology (Berl); 2014 Aug; 231(16):3151-67. PubMed ID: 24577516
[TBL] [Abstract][Full Text] [Related]
7. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
Chen J; Zook D; Crickard L; Tabatabaei A
Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
[TBL] [Abstract][Full Text] [Related]
8. Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).
Trabanco AA; Buijnsters P; Rombouts FJ
Expert Opin Ther Pat; 2016 Aug; 26(8):933-46. PubMed ID: 27321640
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
[TBL] [Abstract][Full Text] [Related]
10. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP/cGMP pathway.
Chen L; Liu K; Wang Y; Liu N; Yao M; Hu J; Wang G; Sun Y; Pan J
Eur J Pharmacol; 2021 Jan; 891():173768. PubMed ID: 33271150
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 2A localized in the spinal cord contributes to inflammatory pain processing.
Kallenborn-Gerhardt W; Lu R; Bothe A; Thomas D; Schlaudraff J; Lorenz JE; Lippold N; Real CI; Ferreirós N; Geisslinger G; Del Turco D; Schmidtko A
Anesthesiology; 2014 Aug; 121(2):372-82. PubMed ID: 24758774
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion.
van Donkelaar EL; Rutten K; Blokland A; Akkerman S; Steinbusch HW; Prickaerts J
Eur J Pharmacol; 2008 Dec; 600(1-3):98-104. PubMed ID: 18957291
[TBL] [Abstract][Full Text] [Related]
14. Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat.
Gu G; Scott T; Yan Y; Warren N; Zhang A; Tabatabaei A; Xu H; Aertgeerts K; Gomez L; Morse A; Li YW; Breitenbucher JG; Massari E; Vivian J; Danks A
J Pharmacol Exp Ther; 2019 Sep; 370(3):399-407. PubMed ID: 31253692
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress.
Xu Y; Pan J; Sun J; Ding L; Ruan L; Reed M; Yu X; Klabnik J; Lin D; Li J; Chen L; Zhang C; Zhang H; O'Donnell JM
Neurobiol Aging; 2015 Feb; 36(2):955-70. PubMed ID: 25442113
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
[TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
Lueptow LM; Zhan CG; O'Donnell JM
Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
[TBL] [Abstract][Full Text] [Related]
18. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
[No Abstract] [Full Text] [Related]
19. Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
Redrobe JP; Rasmussen LK; Christoffersen CT; Bundgaard C; Jørgensen M
Eur J Pharmacol; 2015 Aug; 761():79-85. PubMed ID: 25941078
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
